Article(id=1329869578995348009, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.02.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1666886400000, receivedDateStr=2022-10-28, revisedDate=1673452800000, revisedDateStr=2023-01-12, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995215413, onlineDateStr=2026-11-18, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995215413, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995215413, creator=13701087609, updateTime=1794995215413, updator=13701087609, issue=Issue{id=1329869572141855203, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='2', pageStart='105', pageEnd='196', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995213780, creator='13701087609', updateTime=1794995798529, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872025146995085, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872025146995086, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869572141855203, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=128, endPage=133, ext={EN=ArticleExt(id=1329869579238617642, articleId=1329869578995348009, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a widely used drug for treatment of diabetes mellitus type 2 (T2DM). It is especially effective for patients with metabolic syndrome such as obesity and hyperlipemia. At present, most GLP-1RA administration methods in the world are subcutaneous injection. Oral semaglutide is the first approved oral GLP-1RA daily preparation, which is formulated with the absorption enhancer N-[8-(2-hydroxyphenylmethyl) amino] salcaprozate sodium (SNAC). Oral semaglutide overcome the problem of peptide drug absorption in acidic gastric fluid. When oral smeiglutide is used alone or in combination with other hypoglycemic agents, it can play a good role in controlling blood glucose, reducing body weight and systolic blood pressure, and is well tolerated, and its safety is consistent with that of GLP- 1RA injection. This article reviewed the recent research progress on oral GLP-1RA in the treatment of T2DM, in order to provide clinical reference for clinic.

, authors=Wen LI, Xiaoying DING*, authorsList=Wen LI, Xiaoying DING, authorCompany=null, correspAuthors=Xiaoying DING, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869579540607531, articleId=1329869578995348009, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=口服胰高糖素样肽-1受体激动剂治疗2型糖尿病研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是一种被广泛应用于2型糖尿病(diabetes mellitus type 2,T2DM)治疗的药物,尤其对合并肥胖(obesity)、高脂血症(hyperlipemia)等代谢综合征(metabolic syndrome)的患者疗效良好。目前,国际上GLP-1RA给药方式大多为皮下注射。口服司美格鲁肽(semaglutide)是目前首个被批准上市的口服GLP-1RA日制剂,由司美格鲁肽与吸收增强剂N-[8-(2-羟基苯甲基)氨基]辛酸钠(salcaprozate sodium,SNAC)共同配方,克服了胃液酸性条件下肽类药物吸收的难题。口服司美格鲁肽单独使用或与其他降糖药物联用均可起到良好的控制血糖、降低体质量及收缩压的作用,且耐受性良好,安全性与GLP-1RA注射制剂一致。现综述近年来口服GLP-1RA治疗T2DM的研究进展,旨在为临床提供参考。

, authors=李雯, 丁晓颖*, authorsList=李雯, 丁晓颖, authorCompany=null, correspAuthors=丁晓颖, authorNote=

李雯,主治医师,研究方向:内分泌代谢疾病。

, correspAuthorsNote=
丁晓颖,主任医师,研究方向:内分泌系统疾病的诊治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=S7gfV/LzQUxBcDAoIxhxhQ==, magXml=vnkayqOqj7RH0VREEgOF8g==, pdfUrl=null, pdf=7B3f4VmU7sY4+ceBEZi5Cg==, pdfFileSize=1569659, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=t3rlkL9MwWLDyafSJfusSQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329869579901317680, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869579972620850, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869579901317680, language=EN, stringName=Wen LI, firstName=Wen, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869580039729715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869579901317680, language=CN, stringName=李雯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学附属第一人民医院内分泌代谢科,上海 200080, bio={"content":"

李雯,主治医师,研究方向:内分泌代谢疾病。

"}, bioImg=null, bioContent=

李雯,主治医师,研究方向:内分泌代谢疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869579775488556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, xref=null, ext=[AuthorCompanyExt(id=1329869579779682861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China), AuthorCompanyExt(id=1329869579830014510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学附属第一人民医院内分泌代谢科,上海 200080)])]), Author(id=1329869580106838581, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869580190724663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869580106838581, language=EN, stringName=Xiaoying DING, firstName=Xiaoying, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869580274610744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869580106838581, language=CN, stringName=丁晓颖, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海交通大学附属第一人民医院内分泌代谢科,上海 200080, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869579775488556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, xref=null, ext=[AuthorCompanyExt(id=1329869579779682861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China), AuthorCompanyExt(id=1329869579830014510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学附属第一人民医院内分泌代谢科,上海 200080)])])], keywords=[Keyword(id=1329869580404634169, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, language=EN, orderNo=1, keyword=oral glucagon-like peptide-1 receptor agonist), Keyword(id=1329869580463354426, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, language=EN, orderNo=2, keyword=diabetes mellitus type 2), Keyword(id=1329869580522074683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, language=EN, orderNo=3, keyword=metabolic syndrome), Keyword(id=1329869580597572156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, language=CN, orderNo=1, keyword=口服胰高血糖素样肽-1受体激动剂), Keyword(id=1329869580681458237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, language=CN, orderNo=2, keyword=2型糖尿病), Keyword(id=1329869580748567102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, language=CN, orderNo=3, keyword=代谢综合征)], refs=[Reference(id=1329869580874396223, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843., articleTitle=null, refAbstract=null), Reference(id=1329869580949893696, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S111-S124., articleTitle=null, refAbstract=null), Reference(id=1329869581067334209, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Jing X, Chen J, Dong Y, et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis[J]. Health Qual Life Outcomes, 2018, 16(1): 189., articleTitle=null, refAbstract=null), Reference(id=1329869581188969026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Tobias DK, Tobias DK, Tobias DK, et al. Body-mass index and mortality among adults with incident type 2 diabetes[J]. N Engl J Med, 2014, 370(3): 233-244., articleTitle=null, refAbstract=null), Reference(id=1329869581260272195, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Magkos F, Magkos F, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2020, 16(10): 545-555., articleTitle=null, refAbstract=null), Reference(id=1329869581331575364, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Majumdar SK, Inzucchi SE. Inzucchi. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?[J]. Endocrine, 2013, 44(1): 47-58., articleTitle=null, refAbstract=null), Reference(id=1329869581461598789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight[J]. Int J Clin Pract Suppl, 2007, 154: 19-28., articleTitle=null, refAbstract=null), Reference(id=1329869581516124742, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Fellner C. Novel treatments target type-2 diabetes[J]. PT, 2016, 41(10): 650-653., articleTitle=null, refAbstract=null), Reference(id=1329869581579039303, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375: 1834-1844., articleTitle=null, refAbstract=null), Reference(id=1329869581658731080, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Romera I, Cebrián-Cuenca A, Cebrián-Cuenca A, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes[J]. Diabetes Ther, 2019, 10(1): 5-19., articleTitle=null, refAbstract=null), Reference(id=1329869581725839945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide[J]. J Med Chem, 2015, 58(18): 7370-7380., articleTitle=null, refAbstract=null), Reference(id=1329869581784560202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Drucker DJ. Advances in oral peptide therapeutics[J]. Nat Rev Drug Discov, 2020, 19(4): 277-289., articleTitle=null, refAbstract=null), Reference(id=1329869581839086155, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Reed J, Bain S, Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1[J]. F1000Res, 2020, 9: F1000., articleTitle=null, refAbstract=null), Reference(id=1329869581897806412, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides[J]. Prog Neurobiol, 2010, 92(3): 442-462., articleTitle=null, refAbstract=null), Reference(id=1329869581952332365, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding[J]. Nature, 1996, 379(6560): 69-72., articleTitle=null, refAbstract=null), Reference(id=1329869582044607054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats[J]. Am J Physiol, 1996, 271(4 Pt 2): R848-R856., articleTitle=null, refAbstract=null), Reference(id=1329869582111715919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Vlieghe P, Lisowski V, Martinez J, et al. Synthetic therapeutic peptides: science and market[J]. Drug Discov Today, 2010, 15(1-2): 40-56., articleTitle=null, refAbstract=null), Reference(id=1329869582178824784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Recio C, Maione F, Iqbal AJ, et al. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease[J]. Front Pharmacol, 2016, 7: 526., articleTitle=null, refAbstract=null), Reference(id=1329869582241739345, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Aguirre TA, Teijeiro-Osorio D, Rosa M, et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials[J]. Adv Drug Deliv Rev, 2016, 106(Pt B): 223-241., articleTitle=null, refAbstract=null), Reference(id=1329869582308848210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Chubb B, Gupta P, Gupta J, et al. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis[J]. Diabetes Ther, 2021, 12(5): 1325-1339., articleTitle=null, refAbstract=null), Reference(id=1329869582392734291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Kalra S, Baruah MP, Sahay RK, et al. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future[J]. Indian J Endocrinol Metab, 2016, 20(2): 254-267., articleTitle=null, refAbstract=null), Reference(id=1329869582459843156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes[J]. Diabetes Care, 2019, 42(9): 1724-1732., articleTitle=null, refAbstract=null), Reference(id=1329869582526952021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial[J]. Diabetes Care, 2019, 42(12): 2272-2281., articleTitle=null, refAbstract=null), Reference(id=1329869582585672278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel[J]. J Clin Pharmacol, 2015, 55(5): 497-504., articleTitle=null, refAbstract=null), Reference(id=1329869582644392535, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species[J]. Eur J Pharm Sci, 2017, 104: 31-41., articleTitle=null, refAbstract=null), Reference(id=1329869582707307096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist[J]. Sci Transl Med, 2018, 10(467): eaar7047., articleTitle=null, refAbstract=null), Reference(id=1329869582778610265, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Bækdal TA, Bækdal TA, Navarria A, et al. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide[J]. Expert Opin Drug Metab Toxicol, 2018, 14(8): 869-877., articleTitle=null, refAbstract=null), Reference(id=1329869582849913434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes[J]. Clin Pharmacokinet, 2019, 58(6): 781-791., articleTitle=null, refAbstract=null), Reference(id=1329869582917022299, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity[J]. Diabetes Obes Metab, 2017, 19(9): 1242-1251., articleTitle=null, refAbstract=null), Reference(id=1329869582979936860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Nuhoho S, Gupta J, Hansen BB, et al. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis[J]. Diabetes Ther, 2019, 10(6): 2183-2199., articleTitle=null, refAbstract=null), Reference(id=1329869583042851421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Hunt B, Hansen BB, Ericsson Å, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States[J]. Adv Ther, 2019, 36(12): 3483-3493., articleTitle=null, refAbstract=null), Reference(id=1329869583118348894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Baekdal TA, Donsmark M, Hartoft-Nielsen ML, et al. Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study[J]. Clin Pharmacol Drug Dev, 2021, 10(5): 453-462., articleTitle=null, refAbstract=null), Reference(id=1329869583185457759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Bækdal TA, Borregaard J, Hansen CW, et al. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects[J]. Clin Pharmacokinet, 2019, 58(9): 1193-1203., articleTitle=null, refAbstract=null), Reference(id=1329869583248372320, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2019, 7(7): 515-527., articleTitle=null, refAbstract=null), Reference(id=1329869583311286881, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial[J]. Diabetes Care, 2019, 42(12): 2262-2271., articleTitle=null, refAbstract=null), Reference(id=1329869583382590050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial[J]. Lancet, 2019, 394(10192): 39-50., articleTitle=null, refAbstract=null), Reference(id=1329869583470670435, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2019, 7(7): 528-539., articleTitle=null, refAbstract=null), Reference(id=1329869583546167908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Baekdal TA, Thomsen M, Kupčová V, et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment[J]. J Clin Pharmacol, 2018, 58(10): 1314-1323., articleTitle=null, refAbstract=null), Reference(id=1329869583621665381, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Husain M, Husain M, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2019, 381(9): 841-851., articleTitle=null, refAbstract=null), Reference(id=1329869583684579942, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk[J]. Diabetes Obes Metab, 2020, 22(3): 442-451., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329869579775488556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, xref=null, ext=[AuthorCompanyExt(id=1329869579779682861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China), AuthorCompanyExt(id=1329869579830014510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学附属第一人民医院内分泌代谢科,上海 200080)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.02.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.02.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.02.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
口服胰高糖素样肽-1受体激动剂治疗2型糖尿病研究进展
李雯 , 丁晓颖 *
世界临床药物 | 医药专论 2023,44(2): 128-133
收起
收藏切换
世界临床药物 |医药专论 2023 , 44 (2) : 128 -133
口服胰高糖素样肽-1受体激动剂治疗2型糖尿病研究进展
全屏
[Author(id=1329869579901317680, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869579972620850, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869579901317680, language=EN, stringName=Wen LI, firstName=Wen, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869580039729715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869579901317680, language=CN, stringName=李雯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学附属第一人民医院内分泌代谢科,上海 200080, bio={"content":"

李雯,主治医师,研究方向:内分泌代谢疾病。

"}, bioImg=null, bioContent=

李雯,主治医师,研究方向:内分泌代谢疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869579775488556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, xref=null, ext=[AuthorCompanyExt(id=1329869579779682861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China), AuthorCompanyExt(id=1329869579830014510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学附属第一人民医院内分泌代谢科,上海 200080)])]), Author(id=1329869580106838581, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869580190724663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869580106838581, language=EN, stringName=Xiaoying DING, firstName=Xiaoying, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869580274610744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, authorId=1329869580106838581, language=CN, stringName=丁晓颖, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海交通大学附属第一人民医院内分泌代谢科,上海 200080, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869579775488556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, xref=null, ext=[AuthorCompanyExt(id=1329869579779682861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China), AuthorCompanyExt(id=1329869579830014510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869578995348009, companyId=1329869579775488556, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学附属第一人民医院内分泌代谢科,上海 200080)])])]
李雯, 丁晓颖*
作者信息
  • 上海交通大学附属第一人民医院内分泌代谢科,上海 200080
通讯作者:
丁晓颖,主任医师,研究方向:内分泌系统疾病的诊治。
作者简介:

李雯,主治医师,研究方向:内分泌代谢疾病。

Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2
Wen LI, Xiaoying DING*
Affiliations
  • Department of Endocrinology and Metabolism, Shanghai General Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200080, China
出版时间: 2023-02-10 doi: 10.13683/j.wph.2023.02.005
文章导航
收藏切换

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是一种被广泛应用于2型糖尿病(diabetes mellitus type 2,T2DM)治疗的药物,尤其对合并肥胖(obesity)、高脂血症(hyperlipemia)等代谢综合征(metabolic syndrome)的患者疗效良好。目前,国际上GLP-1RA给药方式大多为皮下注射。口服司美格鲁肽(semaglutide)是目前首个被批准上市的口服GLP-1RA日制剂,由司美格鲁肽与吸收增强剂N-[8-(2-羟基苯甲基)氨基]辛酸钠(salcaprozate sodium,SNAC)共同配方,克服了胃液酸性条件下肽类药物吸收的难题。口服司美格鲁肽单独使用或与其他降糖药物联用均可起到良好的控制血糖、降低体质量及收缩压的作用,且耐受性良好,安全性与GLP-1RA注射制剂一致。现综述近年来口服GLP-1RA治疗T2DM的研究进展,旨在为临床提供参考。

口服胰高血糖素样肽-1受体激动剂  /  2型糖尿病  /  代谢综合征

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a widely used drug for treatment of diabetes mellitus type 2 (T2DM). It is especially effective for patients with metabolic syndrome such as obesity and hyperlipemia. At present, most GLP-1RA administration methods in the world are subcutaneous injection. Oral semaglutide is the first approved oral GLP-1RA daily preparation, which is formulated with the absorption enhancer N-[8-(2-hydroxyphenylmethyl) amino] salcaprozate sodium (SNAC). Oral semaglutide overcome the problem of peptide drug absorption in acidic gastric fluid. When oral smeiglutide is used alone or in combination with other hypoglycemic agents, it can play a good role in controlling blood glucose, reducing body weight and systolic blood pressure, and is well tolerated, and its safety is consistent with that of GLP- 1RA injection. This article reviewed the recent research progress on oral GLP-1RA in the treatment of T2DM, in order to provide clinical reference for clinic.

oral glucagon-like peptide-1 receptor agonist  /  diabetes mellitus type 2  /  metabolic syndrome
李雯, 丁晓颖. 口服胰高糖素样肽-1受体激动剂治疗2型糖尿病研究进展. 世界临床药物, 2023 , 44 (2) : 128 -133 . DOI: 10.13683/j.wph.2023.02.005
Wen LI, Xiaoying DING. Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2[J]. World Clinical Drug, 2023 , 44 (2) : 128 -133 . DOI: 10.13683/j.wph.2023.02.005

参考文献 引证文献
排序方式:
[1]
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843.
[2]
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S111-S124.
[3]
Jing X, Chen J, Dong Y, et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis[J]. Health Qual Life Outcomes, 2018, 16(1): 189.
[4]
Tobias DK, Tobias DK, Tobias DK, et al. Body-mass index and mortality among adults with incident type 2 diabetes[J]. N Engl J Med, 2014, 370(3): 233-244.
[5]
Magkos F, Magkos F, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2020, 16(10): 545-555.
[6]
Majumdar SK, Inzucchi SE. Inzucchi. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?[J]. Endocrine, 2013, 44(1): 47-58.
[7]
Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight[J]. Int J Clin Pract Suppl, 2007, 154: 19-28.
[8]
Fellner C. Novel treatments target type-2 diabetes[J]. PT, 2016, 41(10): 650-653.
[9]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375: 1834-1844.
[10]
Romera I, Cebrián-Cuenca A, Cebrián-Cuenca A, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes[J]. Diabetes Ther, 2019, 10(1): 5-19.
[11]
Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide[J]. J Med Chem, 2015, 58(18): 7370-7380.
[12]
Drucker DJ. Advances in oral peptide therapeutics[J]. Nat Rev Drug Discov, 2020, 19(4): 277-289.
[13]
Reed J, Bain S, Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1[J]. F1000Res, 2020, 9: F1000.
[14]
Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides[J]. Prog Neurobiol, 2010, 92(3): 442-462.
[15]
Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding[J]. Nature, 1996, 379(6560): 69-72.
[16]
Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats[J]. Am J Physiol, 1996, 271(4 Pt 2): R848-R856.
[17]
Vlieghe P, Lisowski V, Martinez J, et al. Synthetic therapeutic peptides: science and market[J]. Drug Discov Today, 2010, 15(1-2): 40-56.
[18]
Recio C, Maione F, Iqbal AJ, et al. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease[J]. Front Pharmacol, 2016, 7: 526.
[19]
Aguirre TA, Teijeiro-Osorio D, Rosa M, et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials[J]. Adv Drug Deliv Rev, 2016, 106(Pt B): 223-241.
[20]
Chubb B, Gupta P, Gupta J, et al. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis[J]. Diabetes Ther, 2021, 12(5): 1325-1339.
[21]
Kalra S, Baruah MP, Sahay RK, et al. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future[J]. Indian J Endocrinol Metab, 2016, 20(2): 254-267.
[22]
Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes[J]. Diabetes Care, 2019, 42(9): 1724-1732.
[23]
Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial[J]. Diabetes Care, 2019, 42(12): 2272-2281.
[24]
Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel[J]. J Clin Pharmacol, 2015, 55(5): 497-504.
[25]
Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species[J]. Eur J Pharm Sci, 2017, 104: 31-41.
[26]
Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist[J]. Sci Transl Med, 2018, 10(467): eaar7047.
[27]
Bækdal TA, Bækdal TA, Navarria A, et al. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide[J]. Expert Opin Drug Metab Toxicol, 2018, 14(8): 869-877.
[28]
Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes[J]. Clin Pharmacokinet, 2019, 58(6): 781-791.
[29]
Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity[J]. Diabetes Obes Metab, 2017, 19(9): 1242-1251.
[30]
Nuhoho S, Gupta J, Hansen BB, et al. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis[J]. Diabetes Ther, 2019, 10(6): 2183-2199.
[31]
Hunt B, Hansen BB, Ericsson Å, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States[J]. Adv Ther, 2019, 36(12): 3483-3493.
[32]
Baekdal TA, Donsmark M, Hartoft-Nielsen ML, et al. Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study[J]. Clin Pharmacol Drug Dev, 2021, 10(5): 453-462.
[33]
Bækdal TA, Borregaard J, Hansen CW, et al. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects[J]. Clin Pharmacokinet, 2019, 58(9): 1193-1203.
[34]
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2019, 7(7): 515-527.
[35]
Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial[J]. Diabetes Care, 2019, 42(12): 2262-2271.
[36]
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial[J]. Lancet, 2019, 394(10192): 39-50.
[37]
Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2019, 7(7): 528-539.
[38]
Baekdal TA, Thomsen M, Kupčová V, et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment[J]. J Clin Pharmacol, 2018, 58(10): 1314-1323.
[39]
Husain M, Husain M, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2019, 381(9): 841-851.
[40]
Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk[J]. Diabetes Obes Metab, 2020, 22(3): 442-451.
2023年第44卷第2期
19
6
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.02.005
  • 接收时间:2022-10-28
  • 首发时间:2026-11-18
  • 出版时间:2023-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-10-28
  • 修回日期:2023-01-12
基金
作者信息
    上海交通大学附属第一人民医院内分泌代谢科,上海 200080

通讯作者:

丁晓颖,主任医师,研究方向:内分泌系统疾病的诊治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.02.005
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏